Francisco B.
- Country
- Spain
- Department
- ES10008: Hematología
Research Overview
- Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Long-term Safety and Efficacy of Enpatoran in Subacute Cutaneous, Discoid, and Systemic Lupus Erythematosus Post-WILLOW Study Completion
- Evaluation of GS-0151 in Patients With Rheumatoid Arthritis: A Clinical Trial
Data & Insights
Has run more than one trial at 410 of 683 partner sites.
Specializations
Oncological Research
This investigator specializes in studying innovative treatment approaches for locally advanced colon cancer (LACC), with particular emphasis on the integration of neoadjuvant chemotherapy in treatment protocols.
- Advanced Colorectal Oncology
- Neoadjuvant Treatment Strategies
- Surgical Oncology
The investigator's work focuses on evaluating treatment effectiveness and improving disease-free survival rates in colorectal cancer patients.
Treatment Optimization
Key research interests include developing enhanced therapeutic protocols combining multimodal treatment approaches for colon cancer management.
- Combined Therapy Protocols
- Pre-operative Treatment Planning
- Post-surgical Care Optimization
The investigator explores the timing and sequencing of different therapeutic interventions in advanced colorectal cancer treatment.
Clinical Outcomes
Research efforts concentrate on measuring and improving patient outcomes in complex colon cancer cases, with particular attention to survival metrics.
- Survival Rate Analysis
- Treatment Response Assessment
- Long-term Outcome Evaluation
The investigator examines the effectiveness of various treatment sequences in managing locally advanced disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.